Clinical Trial Update: Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating systemic everolimus to prevent major adverse cardiac events after bare metal stent implantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Restenosis

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: German Heart Institute | Conditions: Coronary Artery Disease, Coronary Restenosis | Phase 3 | Status: UNKNOWN